HUE047542T2 - A rák kombinált kezelése - Google Patents

A rák kombinált kezelése

Info

Publication number
HUE047542T2
HUE047542T2 HUE17726573A HUE17726573A HUE047542T2 HU E047542 T2 HUE047542 T2 HU E047542T2 HU E17726573 A HUE17726573 A HU E17726573A HU E17726573 A HUE17726573 A HU E17726573A HU E047542 T2 HUE047542 T2 HU E047542T2
Authority
HU
Hungary
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
HUE17726573A
Other languages
English (en)
Inventor
Nils Bruenner
Palle Christophersen
Jan Stenvang
Jens Lichtenberg
Annemette Thougaard
Original Assignee
Scandion Oncology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology As filed Critical Scandion Oncology As
Publication of HUE047542T2 publication Critical patent/HUE047542T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17726573A 2016-05-17 2017-05-17 A rák kombinált kezelése HUE047542T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17

Publications (1)

Publication Number Publication Date
HUE047542T2 true HUE047542T2 (hu) 2020-04-28

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19205104A HUE053744T2 (hu) 2016-05-17 2017-05-17 A rák kombinált kezelése
HUE17726573A HUE047542T2 (hu) 2016-05-17 2017-05-17 A rák kombinált kezelése

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE19205104A HUE053744T2 (hu) 2016-05-17 2017-05-17 A rák kombinált kezelése

Country Status (18)

Country Link
US (2) US11103481B2 (hu)
EP (3) EP3458052B1 (hu)
JP (1) JP7033554B2 (hu)
CN (1) CN109475535A (hu)
AU (1) AU2017266724B2 (hu)
BR (1) BR112018073518A2 (hu)
CA (1) CA3023202A1 (hu)
CY (2) CY1122541T1 (hu)
DK (2) DK3622953T3 (hu)
ES (2) ES2770374T3 (hu)
HR (2) HRP20200076T1 (hu)
HU (2) HUE053744T2 (hu)
LT (2) LT3458052T (hu)
PL (2) PL3458052T3 (hu)
PT (2) PT3458052T (hu)
RS (2) RS61786B1 (hu)
SI (2) SI3622953T1 (hu)
WO (1) WO2017198700A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3458052T (lt) * 2016-05-17 2020-02-10 Scandion Oncology A/S Vėžio kombinuotas gydymas
WO2019165158A1 (en) * 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
EP3846802A1 (en) * 2018-09-06 2021-07-14 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en) 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
EP4355322A1 (en) 2021-06-14 2024-04-24 Scandion Oncology A/S Methods of increasing the plasma drug exposure of anticancer agents
AU2022295049A1 (en) 2021-06-14 2023-12-14 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN117229258A (zh) * 2022-06-07 2023-12-15 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
CZ295822B6 (cs) 1997-04-22 2005-11-16 Neurosearch A/S Substituované fenylderiváty, způsob jejich přípravy a použití a farmaceutické přípravky s jejich obsahem
PT1123274E (pt) 1998-10-22 2005-04-29 Neurosearch As Derivados de fenilo substituido, sua preparacao e utilizacao
US20060058395A1 (en) * 2002-08-01 2006-03-16 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
DK1638948T3 (da) 2003-06-17 2009-02-02 Neurosearch As Diphenylurinstofderivater og deres anvendelse som chloridkanalblokkere
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
US20070293553A1 (en) 2004-12-17 2007-12-20 Dahl Bjarne H Diphenylurea Derivatives Useful As Potassium Channel Activators
MX2008011409A (es) * 2006-03-14 2008-09-22 Neurosearch As Derivados de difenilurea y su uso como bloqueadores de canal de cloruro o moduladores del canal bkca.
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft LRRC8 proteins and protein complexes and methods for identification of channel modulators
ES2662822T3 (es) 2015-03-04 2018-04-09 Scandion Oncology A/S Derivados de 4-amino-3-fenilamino-6-fenilpirazol[3,4-d]pirimidina para uso como inhibidores de la BCRP en tratamientos terapéuticos
LT3458052T (lt) * 2016-05-17 2020-02-10 Scandion Oncology A/S Vėžio kombinuotas gydymas

Also Published As

Publication number Publication date
PT3622953T (pt) 2021-04-21
US20190269654A1 (en) 2019-09-05
EP3622953B1 (en) 2021-03-17
DK3622953T3 (da) 2021-04-26
HUE053744T2 (hu) 2021-07-28
PL3622953T3 (pl) 2021-08-16
WO2017198700A1 (en) 2017-11-23
PT3458052T (pt) 2020-02-03
HRP20200076T1 (hr) 2020-04-03
CY1122541T1 (el) 2021-01-27
EP3854393A1 (en) 2021-07-28
HRP20210572T1 (hr) 2021-05-14
EP3458052B1 (en) 2019-11-06
CA3023202A1 (en) 2017-11-23
SI3458052T1 (sl) 2020-04-30
PL3458052T3 (pl) 2020-06-29
CY1124242T1 (el) 2022-07-22
BR112018073518A2 (pt) 2019-03-19
CN109475535A (zh) 2019-03-15
AU2017266724A1 (en) 2018-12-20
US20210353596A1 (en) 2021-11-18
DK3458052T3 (da) 2020-02-03
US11103481B2 (en) 2021-08-31
AU2017266724B2 (en) 2022-04-14
EP3622953A1 (en) 2020-03-18
SI3622953T1 (sl) 2021-05-31
JP7033554B2 (ja) 2022-03-10
RS61786B1 (sr) 2021-06-30
RS59844B1 (sr) 2020-02-28
ES2770374T3 (es) 2020-07-01
LT3622953T (lt) 2021-04-26
EP3458052A1 (en) 2019-03-27
ES2870805T3 (es) 2021-10-27
JP2019519506A (ja) 2019-07-11
LT3458052T (lt) 2020-02-10
US11903927B2 (en) 2024-02-20

Similar Documents

Publication Publication Date Title
HK1247129A1 (zh) 治療癌症的聯合療法
IL261959B1 (en) Cancer treatment with tg02
HK1251475A1 (zh) 用於癌症治療的聯合療法
PL3622953T3 (pl) Leczenie skojarzone nowotworu
IL259996A (en) Combinations for cancer treatment
IL265697B1 (en) Prostate cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
HK1251794A1 (zh) 癌症治療
GB201408297D0 (en) Treatment of cancer
IL274748A (en) Improved cancer treatment
GB201417456D0 (en) Treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer